1
|
Lee SH, Heng D, Xavier VJ, Chan KP, Ng WK, Zhao Y, Chan HK, Tan RB. Inhaled non-steroidal polyphenolic alternatives for anti-inflammatory combination therapy. POWDER TECHNOL 2018. [DOI: 10.1016/j.powtec.2018.08.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
2
|
Zhu J, Bandi V, Qiu S, Figueroa DJ, Evans JF, Barnes N, Guntupalli KK, Jeffery PK. Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD. Chest 2012; 142:347-357. [PMID: 22871757 DOI: 10.1378/chest.11-1581] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Cysteinyl leukotriene 1 (CysLT1) receptor expression is known to be increased in the airway mucosa of patients with asthma, especially during exacerbations; however, nothing is known of its expression in COPD. METHODS We applied immunohistochemistry and in situ hybridization to endobronchial biopsies to determine inflammatory cell CysLT1 receptor protein and mRNA expression in the following: (1) 15 nonsmoker control subjects (NSC), (2) 16 smokers with moderate to severe COPD in its stable phase (S-COPD), and (3) 15 smokers with COPD hospitalized for a severe exacerbation (SE-COPD). RESULTS The total number of bronchial mucosal inflammatory cells (CD45+) and those expressing CysLT1 receptor protein were significantly greater in SE-COPD (CysLT1 receptor protein: median [range] = 139 [31-634]) as compared with S-COPD (32 [6-114]) or NSC (16 [4-66]) (P < .001 for both). CysLT1 receptor gene expression showed similar differences. A greater proportion of CD451 cells expressed CysLT1 receptor protein in SE-COPD (median [range] = 22% [8-81]) compared with S-COPD (10% [4-32]) (P < .03) or NSC (7% [1-19]) (P < .002). In SE-COPD, the relative frequencies of CysLT1 receptor-expressing cells were as follows: tryptase1 mast cells > CD681 monocytes/macrophage > neutrophils > CD201 B lymphocytes = EG21 eosinophils. Moreover, there were positive correlations between the numbers of cells expressing CysLT1 receptor protein and the numbers of CD451 cells (r = 0.78; P < .003) and tryptase1 mast cells (r = 0.62; P < .02). CONCLUSIONS Bronchial mucosal CysLT1 receptor-positive inflammatory cells are present in the bronchial mucosa in COPD in greatest number in those experiencing a severe exacerbation.
Collapse
Affiliation(s)
- Jie Zhu
- Lung Pathology Unit, Department of Respiratory Medicine, Imperial College London, London, England
| | - Venkata Bandi
- Department of Medicine, Baylor College of Medicine, Ben Taub General Hospital, Houston, TX
| | - Shengyang Qiu
- Lung Pathology Unit, Department of Respiratory Medicine, Imperial College London, London, England
| | | | - Jilly F Evans
- Department of Pharmacology, Merck & Co Inc, West Point, PA
| | - Neil Barnes
- Department of Respiratory Medicine, Barts and The London Hospital, London, England
| | - Kay K Guntupalli
- Department of Medicine, Baylor College of Medicine, Ben Taub General Hospital, Houston, TX
| | - Peter K Jeffery
- Lung Pathology Unit, Department of Respiratory Medicine, Imperial College London, London, England.
| |
Collapse
|
3
|
Fatal adverse reaction to ketorolac tromethamine in asthmatic patient. Am J Forensic Med Pathol 2009; 29:358-63. [PMID: 19259027 DOI: 10.1097/paf.0b013e318185a00a] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
A case of an asthmatic woman who collapsed within a few minutes after intramuscular ketorolac tromethamine (KT) injection is reported. Autopsy findings revealed anatomic evidence of a recent asthma attack. KT was found to be present in the blood at a concentration within the therapeutic range and consistent with the administered dose. Based on the timing of the collapse in relation to the KT administration, death was attributed to an adverse reaction to KT, resulting in acute bronchospasm and cardiac arrest, with asthma as an underlying contributing factor. In this case, asthma alone was not responsible for the death of the patient but only a contributing factor. Physicians have to be aware that in asthmatic patients bronchospasm can be induced by drugs among which aspirin or nonsteroidal anti-inflammatory drugs such as KT are the most common; therefore, death may have an iatrogenic cause. The paper also describes the pathogenic mechanism of an adverse reaction to such drugs and analytical methods for the isolation and detection of KT in postmortem blood.
Collapse
|
4
|
Ramsay CF, Sullivan P, Gizycki M, Wang D, Swern AS, Barnes NC, Reiss TF, Jeffery PK. Montelukast and bronchial inflammation in asthma: a randomised, double-blind placebo-controlled trial. Respir Med 2009; 103:995-1003. [PMID: 19249198 DOI: 10.1016/j.rmed.2009.01.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2008] [Revised: 01/19/2009] [Accepted: 01/19/2009] [Indexed: 10/21/2022]
Abstract
BACKGROUND Examination of bronchoalveolar lavage, induced sputum, and peripheral blood indicate that cysteinyl leukotriene receptor blockers decrease inflammatory cells in asthma but these do not examine airway tissue per se. OBJECTIVES Our objective was to determine the effect of montelukast, a leukotriene receptor antagonist, on airway tissue inflammatory cells by direct bronchoscopic examination of the bronchial mucosa. METHODS Adult subjects with mild asthma (pre-bronchodilator FEV(1)> or =70% predicted; PC(20) of < or =4 mg/mL) were given 10mg/day oral montelukast (N=38) or placebo (N=37) for 6 weeks. Bronchial mucosal eosinophils and mast cells were identified and counted. RESULTS Change from baseline in numbers of biopsy EG2+ ("activated") eosinophils was the primary endpoint; numbers of total (chromotrope 2R+) eosinophils and (tryptase+) mast cells were secondary. Unexpectedly, there were many patients with zero EG2+ eosinophils at baseline. There was a within-group decrease in EG2+ cells, from 13.54 cells/mm (at baseline) to 0.79 cells/mm at 6 weeks in the montelukast group (LS mean change; 95% confidence interval=-13.59 [-25.45, -1.74]cells/mm; P<0.05), a change not observed in the placebo group (-1.17 [-13.26, 10.91]cells/mm; NS). The zero-inflated Poisson statistical model demonstrated that montelukast significantly reduced post-treatment EG2+ cells by 80% compared with placebo (95% CI [70.6-86.8%]; P<0.0001). The data for total eosinophils showed similar changes. The reduction in mast cell numbers was 12% (95% CI [7.9, 16.0]; P<0.0001). CONCLUSION Direct examination of airway tissue confirms that montelukast decreases the number of eosinophils and mast cells in asthma.
Collapse
Affiliation(s)
- C F Ramsay
- Department of Respiratory Medicine, Royal London Hospital, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Ammit AJ, Burgess JK, Hirst SJ, Hughes JM, Kaur M, Lau JY, Zuyderduyn S. The effect of asthma therapeutics on signalling and transcriptional regulation of airway smooth muscle function. Pulm Pharmacol Ther 2008; 22:446-54. [PMID: 19022391 DOI: 10.1016/j.pupt.2008.10.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2008] [Revised: 10/02/2008] [Accepted: 10/22/2008] [Indexed: 01/11/2023]
Abstract
SCOPE OF THE REVIEW Our knowledge of the multifunctional nature of airway smooth muscle (ASM) has expanded rapidly in the last decade, but the underlying molecular mechanisms and how current therapies for obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), affect these are still being elucidated. Our current knowledge has built on the pharmacology of human ASM contraction and relaxation established prior to that and which is reviewed in detail elsewhere in this issue. The advent of methods to isolate and culture ASM cells, especially human ASM cells, has made it possible to study how they may contribute to airway remodelling through their synthetic, proliferative, and migratory capacities. Now the underlying molecular mechanisms of ASM growth factor secretion, extracellular matrix (ECM) production, proliferation and migration, as well as contraction and relaxation, are being determined. A complex network of signalling pathways leading to gene transcription in ASM cells permits this functional plasticity in healthy and diseased airways. This review is an overview of the effects of current therapies, and some of those in development, on key signalling pathways and transcription factors involved in these ASM functions.
Collapse
Affiliation(s)
- Alaina J Ammit
- Respiratory Research Group, Faculty of Pharmacy, University of Sydney, NSW, Australia.
| | | | | | | | | | | | | |
Collapse
|
6
|
Wahrendorf MS, Wink M. Pharmacologically active natural products in the defence secretion of Palembus ocularis (Tenebrionidae, Coleoptera). JOURNAL OF ETHNOPHARMACOLOGY 2006; 106:51-6. [PMID: 16417979 DOI: 10.1016/j.jep.2005.12.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2004] [Revised: 12/01/2005] [Accepted: 12/01/2005] [Indexed: 05/06/2023]
Abstract
The tenebrioid beetle Palembus ocularis Casey 1891 has been used in the traditional medicine of Central and South America to treat Asthma bronchiale. Palembus ocularis has large pygidial glands filled with defence chemicals. The defence fluid was analysed by GLC and GLC-MS. The main components are quinones, such as hydroquinone, 2-ethylhydroquinone as major and 2-methylhydroquinone as minor metabolite. Furthermore, terpenes, fatty acids and their esters, cholesterol and lactones were discovered, with 1-pentadecene as a major component. Pharmacological experiments were carried out with the defence fluid and isolated compounds in order to find out if a rational base exists for the use in traditional medicine. 5-Lipoxygenase is inhibited by crude extracts and hydroquinone. Moreover, a combination of different hydroquinones was 20-times more effective than individual substances suggesting a synergistic effect. The inhibitory effect could be further increased with addition of 1-pentadecene. Anti-inflammatory activity was determined by HET-CAM. The polar extracts of Palembus ocularis showed anti-inflammatory activity in this system. Pure hydroquinone exhibited a similar activity as crude extracts indicating that it constitutes the active principle. The 5-LOX and HET-CAM-assays provide good evidence that hydroquinones in the defence fluid of Palembus ocularis have anti-inflammatory properties which would explain the traditional use of this beetle to treat asthma.
Collapse
Affiliation(s)
- Marit-Saskia Wahrendorf
- Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg, Germany
| | | |
Collapse
|
7
|
Zhu J, Qiu YS, Figueroa DJ, Bandi V, Galczenski H, Hamada K, Guntupalli KK, Evans JF, Jeffery PK. Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 2005; 33:531-40. [PMID: 16123393 DOI: 10.1165/rcmb.2005-0124oc] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
We have tested the hypothesis that the CysLT(1) receptor is expressed by a variety of bronchial mucosal immune cells and that the numbers of these cells increase in asthma, when stable and in exacerbations. We have applied in situ hybridization and immunohistochemistry to endobronchial biopsy tissue to identify and count inflammatory cells expressing CysLT(1) receptor mRNA and protein, respectively, and used double immunohistochemistry to identify the specific cell immunophenotypes expressing the receptor. Double-labeling demonstrated that bronchial mucosal eosinophils, neutrophils, mast cells, macrophages, B-lymphocytes, and plasma cells, but not T-lymphocytes, expressed the CysLT(1) receptor. The numbers of CysLT(1) receptor mRNA and protein positive inflammatory cells in nonsmoking, nonatopic control subjects without asthma were 13 and 16 mm(-2), respectively (median values; n = 15), and were significantly greater in stable asthma (50 and 43 mm(-2), respectively; n = 17; P < 0.001). Compared with stable asthma, there were further significant increases in subjects hospitalized for a severe exacerbation of their asthma (mRNA: median = 113 and protein: 156 mm(-2); n = 15; P < 0.002). For the combined data of both asthma subgroups, there were strong positive correlations between the increased numbers of CD45+ leukocytes and the greater numbers of cells expressing CysLT(1) receptor (mRNA: r = 0.60, P < 0.001; protein: r = 0.73, P < 0.0001). In conclusion, a variety of immunohistologically distinct inflammatory cells express the CysLT(1) receptor in the bronchial mucosa and both these and the total number of leukocytes increase in mild stable disease and increase further when there is a severe exacerbation of asthma.
Collapse
Affiliation(s)
- Jie Zhu
- Lung Pathology, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
|
9
|
Ishiwara M, Aoki Y, Takagaki H, Ui M, Okajima F. TA-270 [4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], an anti-asthmatic agent, inhibits leukotriene production induced by IgE receptor stimulation in RBL-2H3 cells. J Pharmacol Exp Ther 2003; 307:583-8. [PMID: 12970384 DOI: 10.1124/jpet.103.055145] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
A novel quinolinone derivative, TA-270 [4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], has been shown to inhibit antigen-induced asthmatic responses including the early-phase bronchoconstriction in actively sensitized guinea pigs. Here we characterized the action mechanisms of TA-270 in cellular level in vitro. In RBL-2H3 mast cells sensitized with dinitrophenol (DNP)-specific IgE, the antigen exhibited several mast cell functions, including hexosaminidase release as a marker of degranulation, production of tumor necrosis factor-alpha, and production of immunologically detective leukotrienes. These antigen-induced actions were associated with the activation of several early signaling events, including inositol phosphate production reflecting phospholipase C activation and extracellular signal-regulated kinase activation. When the cells were treated with TA-270, the antigen-induced leukotriene production was almost completely suppressed, but other antigen-induced actions listed above were hardly affected. This drug also failed to affect the antigen-induced phospholipase A2 activation as evaluated by the total release of arachidonic acid and its metabolites from the cells prelabeled with radioactive arachidonic acid. However, TA-270 clearly changed the arachidonic acid metabolic pathway. It suppressed the accumulation of 5-lipoxygenase products, including leukotrienes, but hardly affected the accumulation of cyclooxygenase products. The inhibitory action of TA-270 on leukotriene production was also observed in human neutrophils and eosinophils. We conclude that TA-270 inhibits 5-lipoxygenase activity and, thereby, suppresses the antigen-induced leukotriene production.
Collapse
Affiliation(s)
- Mitsuteru Ishiwara
- Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi 371-8512, Japan.
| | | | | | | | | |
Collapse
|
10
|
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs), which for so many years have played major roles in treating inflammation, pain and fever, have had major recent boosts to various therapeutic aspects. These include the impetus generated by the cyclooxygenase (COX)-2 inhibitors celecoxib and rofecoxib, a greater understanding of NSAID non-prostaglandin modes of action and the use of NSAIDs in cancer and Alzheimer's disease. Many of these aspects are covered in articles in this issue of Expert Opinion on Pharmacotherapy.
Collapse
Affiliation(s)
- A Bennett
- Department of Surgery, The Rayne Institute, Guy's, King's and St Thomas' School of Medicine, King's College, London SE5 9NU, UK.
| |
Collapse
|